SCHEMBL3569303

SCHEMBL3569303

Clc1ccnc2oc(I)c(-c3ccccc3)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 3/20 0.37
NPC1 O15118 7/20 0.36
RAB9A P51151 7/20 0.36
ATM Q13315 1/20 0.36
PIM1 P11309 1/20 0.35
LCK P06239 2/20 0.34
KDR P35968 2/20 0.34
JAK3 P52333 2/20 0.34
AURKA O14965 3/20 0.33
CDK1 P06493 3/20 0.33
CCNB1 P14635 3/20 0.33
GSK3B P49841 2/20 0.33
CDK5 Q00535 2/20 0.33
CDK5R1 Q15078 2/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CCNE2 O96020 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
TSHR P16473 3/20 0.32
ALDH1A1 P00352 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13436251 0.83 TNK2 (0.55) TNK2LCKKDRJAK3AURKA
SCHEMBL2975737 0.78 TNK2 (0.47) TNK2AURKASMN1; SMN2TSHRALDH1A1
SCHEMBL3565845 0.76 AURKA (0.49) TNK2LCKKDRJAK3AURKA
SCHEMBL5254142 0.74 TNK2 (0.43) TNK2LCKKDRJAK3AURKA
SCHEMBL3051089 0.73 TNK2 (0.45) TNK2LCKKDRJAK3AURKA
SCHEMBL6748429 0.73 KDM4E (0.63) TNK2KDRCDK1GSK3BSMN1; SMN2
SCHEMBL18015457 0.67 IGF1R (0.55) KDRAURKASMN1; SMN2ALDH1A1HPGD
SCHEMBL354142 0.67 AURKA (0.33) NPC1RAB9AATMPIM1AURKA
SCHEMBL2970263 0.66 EGFR (0.59) TNK2LCKKDRJAK3AURKA
SCHEMBL6748435 0.65 HPGD (0.50) NPC1RAB9AATMKDRGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
US-7674907-B2 Furanopyridine derivatives and methods of use AMGEN INC. (US) 2010-03-09 US disclosed
EP-1791845-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2007-06-06 EP disclosed
WO-2006130160-A2 FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS AMGEN INC. (US) 2006-12-07 WO disclosed
US-20060046977-A1 Furanopyridine derivatives and methods of use AMGEN INC. 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046977-A1 Furanopyridine derivatives and methods of use LCK, NFATC1, MINK1 TNK2 22/4885NPC1 4177/4885RAB9A 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.